137 related articles for article (PubMed ID: 9692458)
41. Biocompatibility of heparin-coated cardiopulmonary bypass circuits in coronary patients with left ventricular dysfunction is superior to PMEA-coated circuits.
Kutay V; Noyan T; Ozcan S; Melek Y; Ekim H; Yakut C
J Card Surg; 2006; 21(6):572-7. PubMed ID: 17073955
[TBL] [Abstract][Full Text] [Related]
42. Poly-2-methoxyethylacrylate-coated bypass circuits reduce activation of coagulation system and inflammatory response in congenital cardiac surgery.
Suzuki Y; Daitoku K; Minakawa M; Fukui K; Fukuda I
J Artif Organs; 2008; 11(3):111-6. PubMed ID: 18836870
[TBL] [Abstract][Full Text] [Related]
43. Heparin-coated cardiopulmonary bypass circuits and 25% reduction of heparin dose in coronary artery surgery--a clinical study.
Borowiec J; Thelin S; Bagge L; van der Linden J; Thörnö E; Hansson HE
Ups J Med Sci; 1992; 97(1):55-66. PubMed ID: 1523735
[TBL] [Abstract][Full Text] [Related]
44. Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits.
Jansen PG; te Velthuis H; Huybregts RA; Paulus R; Bulder ER; van der Spoel HI; Bezemer PD; Slaats EH; Eijsman L; Wildevuur CR
J Thorac Cardiovasc Surg; 1995 Sep; 110(3):829-34. PubMed ID: 7564452
[TBL] [Abstract][Full Text] [Related]
45. Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass.
Fosse E; Moen O; Johnson E; Semb G; Brockmeier V; Mollnes TE; Fagerhol MK; Venge P
Ann Thorac Surg; 1994 Aug; 58(2):472-7. PubMed ID: 8067851
[TBL] [Abstract][Full Text] [Related]
46. The effects of Carmeda Bioactive Surface on human blood components during simulated extracorporeal circulation.
Korn RL; Fisher CA; Livingston ER; Stenach N; Fishman SJ; Jeevanadam V; Addonizio VP
J Thorac Cardiovasc Surg; 1996 May; 111(5):1073-84. PubMed ID: 8622305
[TBL] [Abstract][Full Text] [Related]
47. Reducing the post-pump syndrome by using heparin-coated circuits, steroids, or aprotinin.
Harig F; Feyrer R; Mahmoud FO; Blum U; von der Emde J
Thorac Cardiovasc Surg; 1999 Apr; 47(2):111-8. PubMed ID: 10363611
[TBL] [Abstract][Full Text] [Related]
48. Clinical performance and biocompatibility of hyaluronan-based heparin-bonded extracorporeal circuits in different risk cohorts.
Gunaydin S; McCusker K; Sari T; Onur MA; Zorlutuna Y
Interact Cardiovasc Thorac Surg; 2010 Mar; 10(3):371-6. PubMed ID: 20026488
[TBL] [Abstract][Full Text] [Related]
49. The impact of allogenic red cell transfusion and coated bypass circuit on the inflammatory response during cardiopulmonary bypass: a randomized study.
Senay S; Toraman F; Gunaydin S; Kilercik M; Karabulut H; Alhan C
Interact Cardiovasc Thorac Surg; 2009 Jan; 8(1):93-9. PubMed ID: 18801802
[TBL] [Abstract][Full Text] [Related]
50. Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass.
Moen O; Høgåsen K; Fosse E; Dregelid E; Brockmeier V; Venge P; Harboe M; Mollnes TE
Ann Thorac Surg; 1997 Jan; 63(1):105-11. PubMed ID: 8993250
[TBL] [Abstract][Full Text] [Related]
51. Completely heparinized cardiopulmonary bypass and reduced systemic heparin: clinical and hemostatic effects.
Ovrum E; Holen EA; Tangen G; Brosstad F; Abdelnoor M; Ringdal MA; Oystese R; Istad R
Ann Thorac Surg; 1995 Aug; 60(2):365-71. PubMed ID: 7646097
[TBL] [Abstract][Full Text] [Related]
52. Improving cardiopulmonary bypass: heparin-coated circuits.
Vocelka C; Lindley G
J Extra Corpor Technol; 2003 Dec; 35(4):312-6. PubMed ID: 14979422
[TBL] [Abstract][Full Text] [Related]
53. Low dose systemic heparinization combined with heparin-coated extracorporeal circulation. Effects related to platelets.
Mirow N; Brinkmann T; Minami K; Tenderich G; Schulte-Eistrup S; Kleesiek K; Körfer R
J Cardiovasc Surg (Torino); 2001 Oct; 42(5):579-85. PubMed ID: 11562580
[TBL] [Abstract][Full Text] [Related]
54. Clinical efficacy of heparin-bonded bypass circuits related to cytokine responses in children.
Ozawa T; Yoshihara K; Koyama N; Watanabe Y; Shiono N; Takanashi Y
Ann Thorac Surg; 2000 Feb; 69(2):584-90. PubMed ID: 10735703
[TBL] [Abstract][Full Text] [Related]
55. Heparin-coated cardiopulmonary bypass equipment. II. Mechanisms for reduced complement activation in vivo.
Videm V; Mollnes TE; Bergh K; Fosse E; Mohr B; Hagve TA; Aasen AO; Svennevig JL
J Thorac Cardiovasc Surg; 1999 Apr; 117(4):803-9. PubMed ID: 10096977
[TBL] [Abstract][Full Text] [Related]
56. Cardiopulmonary bypass with heparin-coated circuits and reduced systemic anticoagulation.
Kuitunen AH; Heikkilä LJ; Salmenperä MT
Ann Thorac Surg; 1997 Feb; 63(2):438-44. PubMed ID: 9033316
[TBL] [Abstract][Full Text] [Related]
57. Plasma-soluble E-selectin after cardiopulmonary bypass in children: is it a marker of the postoperative course?
Paret G; Prince T; Keller N; Dagan O; Sasson Y; Barzilai A; Guthmann D; Barzilay Z
J Cardiothorac Vasc Anesth; 2000 Aug; 14(4):433-7. PubMed ID: 10972611
[TBL] [Abstract][Full Text] [Related]
58. Platelet activation and aggregation during normothermic cardiopulmonary bypass.
Misawa Y; Konishi H; Kawahito K; Fuse K
Jpn J Thorac Cardiovasc Surg; 2001 Jan; 49(1):21-8. PubMed ID: 11233238
[TBL] [Abstract][Full Text] [Related]
59. Influence of PMEA-coated bypass circuits on perioperative inflammatory response.
Ninomiya M; Miyaji K; Takamoto S
Ann Thorac Surg; 2003 Mar; 75(3):913-7; discussion 917-8. PubMed ID: 12645716
[TBL] [Abstract][Full Text] [Related]
60. Heparin-coated circuits reduce myocardial injury in heart or heart-lung transplantation: a prospective, randomized study.
Wan S; LeClerc JL; Antoine M; DeSmet JM; Yim AP; Vincent JL
Ann Thorac Surg; 1999 Oct; 68(4):1230-5. PubMed ID: 10543484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
